DB
AQST icon

Dmitry Balyasny’s Aquestive Therapeutics AQST Stock Holding History

Dmitry Balyasny’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500,000
Closed -$2.79M – 3061
2025
Q3 		$2.79M Buy
+500,000
New +$2.16M ﹤0.01% 1649

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Dmitry Balyasny's AQST Position: Q2 2026 in Review

Dmitry Balyasny reduced its Aquestive Therapeutics (AQST) stake by 74% in Q2 2026, selling an estimated $9.07M and leaving 744,536 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

Dmitry Balyasny first reported a position in AQST in Q3 2021 and has held it in 5 quarters since. The position peaked at $12M in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Dmitry Balyasny held 744,536 shares of Aquestive Therapeutics worth $3.1M as of Q2 2026.
  • Dmitry Balyasny sold 2,156,034 Aquestive Therapeutics shares in Q2 2026, an estimated $9.07M.
  • Aquestive Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1606 holding.
  • Dmitry Balyasny first reported a position in Aquestive Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Dmitry Balyasny's Aquestive Therapeutics position peaked at $12M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.